|Articles|March 13, 2020
NeurologyLive Friday 5 — March 13, 2020
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 13, 2020.
Advertisement
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: COVID-19: Preventive Measures in Multiple Sclerosis Patients and Others on Immuno-Modulators
Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.
2: Psychological Effects of SMA on Children and Adults
Philippa Cheetham, MBChB, MRCS, MD, FRCS, Crystal Proud, MD, and patient Sebastian Mills discuss the psychological impact spinal muscular atrophy can have on children and adults alike.
3: Small Vessel Disease Score Can Improve Dementia Risk Prediction
An analysis of pooled data from 3 longitudinal clinical trials suggests that SVD score, which can be compiled via a rapid visual assessment of clinical MRI scans, may be able to improve the prediction of dementia risk.
4: MRI in the Diagnosis of MS
Expert neurologists outline how the use of MRI has changed the diagnosis of multiple sclerosis and the importance of standardized protocols.
5: Kiran Maski, MD, MPH: Addressing Pediatric Sleep Disorders
The director of the Sleep Clinic at Boston Children’s Hospital discussed the sleep disorders she sees in her practice, and how she and her colleagues best address these pediatric patients.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
NeurologyLive® Friday 5 — September 12, 2025
5